Cargando…

Can American Joint Committee on Cancer prognostic groups be individualized in patients undergoing surgery for Stage IV invasive upper tract Urothelial Carcinoma?

Purpose: We explored whether the modified American Joint Committee on Cancer tumor-node-metastasis prognostic stage group IV can be individualized in a large population-based cohort of surgically treated invasive upper tract urothelial carcinoma (UTUC) patients. Methods: Invasive UTUC patients from...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zaishang, Li, Xueying, Liu, Ying, Fang, Jiequn, Zhang, Xueqi, Xiao, Kefeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7974530/
https://www.ncbi.nlm.nih.gov/pubmed/33754000
http://dx.doi.org/10.7150/jca.50417
_version_ 1783666928867344384
author Li, Zaishang
Li, Xueying
Liu, Ying
Fang, Jiequn
Zhang, Xueqi
Xiao, Kefeng
author_facet Li, Zaishang
Li, Xueying
Liu, Ying
Fang, Jiequn
Zhang, Xueqi
Xiao, Kefeng
author_sort Li, Zaishang
collection PubMed
description Purpose: We explored whether the modified American Joint Committee on Cancer tumor-node-metastasis prognostic stage group IV can be individualized in a large population-based cohort of surgically treated invasive upper tract urothelial carcinoma (UTUC) patients. Methods: Invasive UTUC patients from the Surveillance, Epidemiology and End Results database (2004-2015) were screened for inclusion. A total of 10,482 eligible cases were identified. Cancer-specific survival (CSS) after surgery was analyzed using Kaplan-Meier plots. Results: According to the most recent pathological prognostic group classification, the 5-year mortality rates of T4NxM0 (n=493), TxN1M0 (n=597), TxN2M0 (n=424) and pTxNxM1 (n=677) patients were 41.1% (95% CI 35.2% to 47.0%), 38.6% (95% CI 33.1% to 44.1%), 40.4% (95% CI 33.0% to 47.8%) and 14.2% (95% CI 9.9% to 18.5%), respectively (T4N0M0 vs. TxNxM1, P<0.001; TxN1M0 vs. TxNxM1, P<0.001; TxN2M0 vs. TxNxM1, P<0.001). Stage IV tumors were subdivided on the basis of the mortality data (Modification 1): stage IVa tumors were considered nonmetastatic (T4NxM0, TxN1-2M0; 5-year CSS 39.9%), and stage IVb tumors were considered metastatic (pTxNxM1; 5-year CSS 14.2%). Stage IV tumors were also subdivided according to the grade classification (Modification 2): stage IVa tumors were considered low grade (T4NxM0, TxN1-2M0, TxNxM1; G1-2; n=141), and stage IVb tumors were considered metastatic (T4NxM0, TxN1-2M0, TxNxM1; G3-4; n=2050). The 5-year CSS rates for stage IVa and IVb patients were 76.3% (95% CI 68.7% to 83.9%) and 31.4% (95% CI 28.5% to 34.3%), respectively (P<0.001). Conclusions: Stage IV patients were stratified into two prognostically different risk groups depending on metastasis or grade. The subclassification of stage IV can increase the level of prognostic detail and individualize the prediction of survival in invasive UTUC patients.
format Online
Article
Text
id pubmed-7974530
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-79745302021-03-21 Can American Joint Committee on Cancer prognostic groups be individualized in patients undergoing surgery for Stage IV invasive upper tract Urothelial Carcinoma? Li, Zaishang Li, Xueying Liu, Ying Fang, Jiequn Zhang, Xueqi Xiao, Kefeng J Cancer Research Paper Purpose: We explored whether the modified American Joint Committee on Cancer tumor-node-metastasis prognostic stage group IV can be individualized in a large population-based cohort of surgically treated invasive upper tract urothelial carcinoma (UTUC) patients. Methods: Invasive UTUC patients from the Surveillance, Epidemiology and End Results database (2004-2015) were screened for inclusion. A total of 10,482 eligible cases were identified. Cancer-specific survival (CSS) after surgery was analyzed using Kaplan-Meier plots. Results: According to the most recent pathological prognostic group classification, the 5-year mortality rates of T4NxM0 (n=493), TxN1M0 (n=597), TxN2M0 (n=424) and pTxNxM1 (n=677) patients were 41.1% (95% CI 35.2% to 47.0%), 38.6% (95% CI 33.1% to 44.1%), 40.4% (95% CI 33.0% to 47.8%) and 14.2% (95% CI 9.9% to 18.5%), respectively (T4N0M0 vs. TxNxM1, P<0.001; TxN1M0 vs. TxNxM1, P<0.001; TxN2M0 vs. TxNxM1, P<0.001). Stage IV tumors were subdivided on the basis of the mortality data (Modification 1): stage IVa tumors were considered nonmetastatic (T4NxM0, TxN1-2M0; 5-year CSS 39.9%), and stage IVb tumors were considered metastatic (pTxNxM1; 5-year CSS 14.2%). Stage IV tumors were also subdivided according to the grade classification (Modification 2): stage IVa tumors were considered low grade (T4NxM0, TxN1-2M0, TxNxM1; G1-2; n=141), and stage IVb tumors were considered metastatic (T4NxM0, TxN1-2M0, TxNxM1; G3-4; n=2050). The 5-year CSS rates for stage IVa and IVb patients were 76.3% (95% CI 68.7% to 83.9%) and 31.4% (95% CI 28.5% to 34.3%), respectively (P<0.001). Conclusions: Stage IV patients were stratified into two prognostically different risk groups depending on metastasis or grade. The subclassification of stage IV can increase the level of prognostic detail and individualize the prediction of survival in invasive UTUC patients. Ivyspring International Publisher 2021-02-02 /pmc/articles/PMC7974530/ /pubmed/33754000 http://dx.doi.org/10.7150/jca.50417 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Li, Zaishang
Li, Xueying
Liu, Ying
Fang, Jiequn
Zhang, Xueqi
Xiao, Kefeng
Can American Joint Committee on Cancer prognostic groups be individualized in patients undergoing surgery for Stage IV invasive upper tract Urothelial Carcinoma?
title Can American Joint Committee on Cancer prognostic groups be individualized in patients undergoing surgery for Stage IV invasive upper tract Urothelial Carcinoma?
title_full Can American Joint Committee on Cancer prognostic groups be individualized in patients undergoing surgery for Stage IV invasive upper tract Urothelial Carcinoma?
title_fullStr Can American Joint Committee on Cancer prognostic groups be individualized in patients undergoing surgery for Stage IV invasive upper tract Urothelial Carcinoma?
title_full_unstemmed Can American Joint Committee on Cancer prognostic groups be individualized in patients undergoing surgery for Stage IV invasive upper tract Urothelial Carcinoma?
title_short Can American Joint Committee on Cancer prognostic groups be individualized in patients undergoing surgery for Stage IV invasive upper tract Urothelial Carcinoma?
title_sort can american joint committee on cancer prognostic groups be individualized in patients undergoing surgery for stage iv invasive upper tract urothelial carcinoma?
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7974530/
https://www.ncbi.nlm.nih.gov/pubmed/33754000
http://dx.doi.org/10.7150/jca.50417
work_keys_str_mv AT lizaishang canamericanjointcommitteeoncancerprognosticgroupsbeindividualizedinpatientsundergoingsurgeryforstageivinvasiveuppertracturothelialcarcinoma
AT lixueying canamericanjointcommitteeoncancerprognosticgroupsbeindividualizedinpatientsundergoingsurgeryforstageivinvasiveuppertracturothelialcarcinoma
AT liuying canamericanjointcommitteeoncancerprognosticgroupsbeindividualizedinpatientsundergoingsurgeryforstageivinvasiveuppertracturothelialcarcinoma
AT fangjiequn canamericanjointcommitteeoncancerprognosticgroupsbeindividualizedinpatientsundergoingsurgeryforstageivinvasiveuppertracturothelialcarcinoma
AT zhangxueqi canamericanjointcommitteeoncancerprognosticgroupsbeindividualizedinpatientsundergoingsurgeryforstageivinvasiveuppertracturothelialcarcinoma
AT xiaokefeng canamericanjointcommitteeoncancerprognosticgroupsbeindividualizedinpatientsundergoingsurgeryforstageivinvasiveuppertracturothelialcarcinoma